Most Recent Articles by Nicole Blazek, Senior Clinical Content Editor
Targeted milestones, areas poised for future discoveries, and areas of research that could benefit the most prioritized.
Currently FDA-approved for treating pseudo bulbar affect, the drug also benefits agitation.
The first randomized-controlled clinical trials are underway to assess if early access to amyloid imaging PET scan results can inform treatment decisions for mild cognitive impairment and dementia.
Investigators identified a possible disease-modifying effect of solanezumab as an early treatment for Alzheimer's disease, but the benefit in clinical practice remains unclear.
Among those with mild cognitive impairment, women's cognitive abilities deteriorated twice as quickly as men.
More Articles by Nicole Blazek, Senior Clinical Content Editor
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- FOSTA-SESTA Threatens Sex Worker Livelihoods: What Mental Health Providers Should Know
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Sodium Valproate May Lower Amygdala Volume in Pediatric Bipolar Disorder
- False Positives in Mood Disorders Questionnaire Screening for Bipolar Disorder
- Suicidal Behavior More Likely in Depression, Bipolar Disorder With Mixed Features
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations
- From Abused Child to Serial Killer: Investigating Nature vs Nurture in Methods of Murder
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Novel Parent-Child Interaction Therapy Targets Preschool-Aged Depression
- Brain Activation Predicts Quetiapine Response in Adolescent Bipolar Depression
- Challenges Psychiatrists Face in Treating Patients with Bipolar Disorder
- Parent-Child Interaction Therapy May Improve Depression and Emotional Function
- Identifying Problems of Functioning in Schizophrenia Informs Approaches to Intervention
- Visual Hallucinations in Dementia and Parkinson Disease: Assessment of Patient Experiences